pharma · Critical Limb Ischemia (CLI) · Sarcoma · DSGN
Lxo Ireland Designated
Lxo Ireland Designated Activity Company
Lxo Ireland Designated clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- CARLSBAD, CA, IE
- Programs
- 68
- Drugs
- 61
- Patents
- 201
Lxo Ireland Designated projects
5 ClinicalTrials.gov programs sponsored by Lxo Ireland Designated.
Lxo Ireland Designated has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Hyperbaric bupivacaine+Sufentanil
Lxo Ireland Designated Activity Company
Anesthesia; Functional
1 trial -
Low intensity laser for oral mucositis
Lxo Ireland Designated Activity Company
Oral Mucositis
1 trial -
Pre-dilation side branch
Lxo Ireland Designated Activity Company
Coronary Angiography
1 trial -
Roflumilast alternated days
Lxo Ireland Designated Activity Company
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
Subcutaneous glargine insulin
Lxo Ireland Designated Activity Company
Diabetes Mellitus
1 trial
Frequently asked questions
How many clinical projects does Lxo Ireland Designated have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.